Ra Medical has announced receiving CE mark approval for the Dabra atherectomy system with catheter.
Atherectomy is the removal of the plaque from the arteries, and it differs from angioplasty in which the plaque is not removed and is a minimally invasive endovascular way to treat patients with peripheral arterial disease. It is well reimbursed because of the benefits to the patients. Technavio recently reported that favourable reimbursement will drive growth of atherectomy by 6% per year through 2020, a press release from Ra Medical, states.
Dean Irwin, co-founder and CEO of Ra Medical said: “Providing physicians with a safe, easy-to-use device that removes all types of plaque quickly is something my colleagues and I have been working on for over a quarter of a century. CE marking approval enables physicians around the world to choose the Dabra system that may be safer and more effective for their patients than other treatments. The Dabra’s economics may increase patient access for therapy.”
The first Dabra cases in Europe are expected to be performed this year. The company is currently nearing completion of its US IDE study to support US FDA clearance.